Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 2/20 | 0.32 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 5/20 | 0.32 |
| ▸ | HTR2C | P28335 | 5/20 | 0.32 |
| ▸ | HTR2B | P41595 | 5/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | LHCGR | P22888 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6736989 | 1.00 | PARP1 (0.46) | PARP1LMNATSHRALDH1A1PKM | |
| SCHEMBL13303432 | 0.86 | PARP1 (0.37) | PARP1LMNATSHRCDC7 | |
| SCHEMBL13688300 | 0.86 | PARP1 (0.37) | PARP1LMNATSHRHDAC4HDAC2 | |
| SCHEMBL27848116 | 0.78 | ALDH1A1 (0.55) | PARP1LMNATSHRALDH1A1PKM | |
| SCHEMBL1189771 | 0.78 | ALDH1A1 (0.55) | PARP1LMNATSHRALDH1A1PKM | |
| SCHEMBL2904793 | 0.78 | ALDH1A1 (0.55) | PARP1LMNATSHRALDH1A1PKM | |
| SCHEMBL19546338 | 0.75 | ALDH1A1 (0.52) | PARP1LMNATSHRALDH1A1PKM | |
| SCHEMBL19546339 | 0.75 | ALDH1A1 (0.52) | PARP1LMNATSHRALDH1A1PKM | |
| SCHEMBL1246496 | 0.68 | MEN1 (0.36) | LMNAALDH1A1HDAC4HDAC2HDAC8 | |
| SCHEMBL6053309 | 0.68 | GSK3B (0.46) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-8182695-B2 | Bridged macrocyclic module compositions | WHITEFORD JEFFERY A (US) | 2012-05-22 | — | — | US | disclosed |
| US-8182695-B2 | Bridged macrocyclic module compositions | WHITEFORD JEFFERY A (US) | 2012-05-22 | — | — | US | disclosed |
| US-8110679-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110679-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-7767810-B2 | Macrocyclic modules comprising linked cyclic synthon units for use in the formation of selectively permeable membranes | COVALENT PARTNERS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767810-B2 | Macrocyclic modules comprising linked cyclic synthon units for use in the formation of selectively permeable membranes | COVALENT PARTNERS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100152438-A1 | AMPHIPHILIC MOLECULAR MODULES AND CONSTRUCTS BASED THEREON | COVALENT PARTNERS LLC | 2010-06-17 | — | — | US | disclosed |
| US-7595368-B2 | Nanofilm compositions with polymeric components | COVALENT PARTNERS, LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-7563890-B2 | Amphiphilic molecular modules and constructs based thereon | COVALENT PARTNERS, LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563890-B2 | Amphiphilic molecular modules and constructs based thereon | COVALENT PARTNERS, LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090114596-A1 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090114596-A1 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS LLC | 2009-05-07 | — | — | US | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-7432371-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS, LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432371-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS, LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152438-A1 | AMPHIPHILIC MOLECULAR MODULES AND CONSTRUCTS BASED THEREON | ANXA6, THEM6, ANXA5 | PARP1 3323/4885LMNA 1456/4885TSHR 4398/4885 |
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | PARP1 1497/4885LMNA 1246/4885TSHR 4727/4885 |
| US-20080290034-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | PARP1 1445/4885LMNA 1218/4885TSHR 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.